Q/C Technologies Discloses Extensive Related-Party Deals, High Executive Compensation, and Auditor Change in Amended 10-K

summarizeSummary

Q/C Technologies filed an amended 10-K to include previously omitted Part III information, revealing substantial related-party financings with an entity controlled by the Executive Chairman, generous equity-based compensation for executives and directors, and a recent auditor change.

check_boxKey Events

• Executive Compensation Details

  A new executive compensation agreement for Executive Chairman Joshua Silverman includes a $120,000 annual salary, eligibility for bonuses, and quarterly grants of fully vested restricted stock units (RSUs) valued at $60,000 per grant, plus a cash payment for estimated taxes on RSUs.

• Significant Related-Party Financings

  The company completed Series G ($8.9M) and Series H ($3.0M) private placements with Pharmacyte Biotech Inc., an entity controlled by Executive Chairman Joshua Silverman, totaling $11.9 million in gross proceeds.

• Substantial Consulting Agreements

  New consulting agreements were disclosed with Ocean Avenue Holdings LLC (affiliated with Martin Shkreli) and director Chelsea Voss, each providing $150,000 annually in cash, plus 212,500 restricted shares/RSUs and 212,500 stock options.

• Auditor Change

  The Audit Committee dismissed Stephano Slack and engaged Grassi & Co. as the independent registered public accounting firm on March 9, 2026, marking the second auditor change in a short period.

auto_awesomeAnalysis

This amended 10-K provides critical details previously missing from the company's annual report, shedding light on significant corporate governance and financial practices. The disclosures highlight a pattern of substantial related-party transactions, particularly the Series G and H private placements totaling $11.9 million with Pharmacyte Biotech Inc., an entity controlled by Executive Chairman Joshua Silverman. This raises concerns about potential conflicts of interest and the terms of these dilutive financings for a micro-cap company. Executive compensation, especially for Mr. Silverman, includes a significant annual RSU grant that vests immediately, along with tax gross-ups, representing a high cost relative to the company's market capitalization. Additionally, new consulting agreements with a Martin Shkreli-affiliated entity and a director involve substantial equity grants and cash fees, further contributing to potential dilution. The recent dismissal of Stephano Slack and engagement of Grassi & Co. as auditors, following another change in 2024, is a red flag that could indicate underlying financial reporting or control issues. Investors should be aware of the high operational costs, concentrated ownership, and potential for significant dilution revealed in these disclosures, especially given the company's prior "going concern" warnings and strategic pivot.